Correlation Between Supernus Pharmaceuticals and Medicure

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Supernus Pharmaceuticals and Medicure at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Supernus Pharmaceuticals and Medicure into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Supernus Pharmaceuticals and Medicure, you can compare the effects of market volatilities on Supernus Pharmaceuticals and Medicure and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Supernus Pharmaceuticals with a short position of Medicure. Check out your portfolio center. Please also check ongoing floating volatility patterns of Supernus Pharmaceuticals and Medicure.

Diversification Opportunities for Supernus Pharmaceuticals and Medicure

-0.43
  Correlation Coefficient

Very good diversification

The 3 months correlation between Supernus and Medicure is -0.43. Overlapping area represents the amount of risk that can be diversified away by holding Supernus Pharmaceuticals and Medicure in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medicure and Supernus Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Supernus Pharmaceuticals are associated (or correlated) with Medicure. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medicure has no effect on the direction of Supernus Pharmaceuticals i.e., Supernus Pharmaceuticals and Medicure go up and down completely randomly.

Pair Corralation between Supernus Pharmaceuticals and Medicure

Given the investment horizon of 90 days Supernus Pharmaceuticals is expected to generate 1.12 times less return on investment than Medicure. But when comparing it to its historical volatility, Supernus Pharmaceuticals is 1.86 times less risky than Medicure. It trades about 0.02 of its potential returns per unit of risk. Medicure is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  85.00  in Medicure on August 30, 2024 and sell it today you would lose (17.00) from holding Medicure or give up 20.0% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Supernus Pharmaceuticals  vs.  Medicure

 Performance 
       Timeline  
Supernus Pharmaceuticals 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Supernus Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Supernus Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in December 2024.
Medicure 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Medicure has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest conflicting performance, the Stock's forward-looking indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.

Supernus Pharmaceuticals and Medicure Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Supernus Pharmaceuticals and Medicure

The main advantage of trading using opposite Supernus Pharmaceuticals and Medicure positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Supernus Pharmaceuticals position performs unexpectedly, Medicure can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicure will offset losses from the drop in Medicure's long position.
The idea behind Supernus Pharmaceuticals and Medicure pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Complementary Tools

Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios